GLP1R and fatty liver disease: Importantly, hepatic lipid content observed after treatment with the high dosages of CNTO3649 and exendin-4 group did not differ from that of the chow control group (P>0.05), suggesting that GLP-1 receptor agonism completely reversed HFD-induced hepatic steatosis.